Article Details

William Blair Maintains Their Buy Rating on Allakos (ALLK)

Retrieved on: 2021-05-28 15:45:00

Tags for this article:

Click the tags to see associated articles and topics

William Blair Maintains Their Buy Rating on Allakos (ALLK). View article details on hiswai:

Excerpt

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of ...

Article found on: www.smarteranalyst.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up